Anzeige
Mehr »
Login
Donnerstag, 06.05.2021 Börsentäglich über 12.000 News von 660 internationalen Medien
Halo Collective setzt neue Meilensteine!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 850727 ISIN: FR0000120271 Ticker-Symbol: TOTB 
Xetra
05.05.21
17:35 Uhr
39,015 Euro
+1,345
+3,57 %
1-Jahres-Chart
TOTAL SE Chart 1 Jahr
5-Tage-Chart
TOTAL SE 5-Tage-Chart
RealtimeGeldBriefZeit
38,89038,99505.05.
38,85538,98005.05.
Dow Jones News
2.107 Leser
Artikel bewerten:
(2)

EQS-Adhoc: Medacta Group SA: Medacta to Introduce NextAR: First FDA-Cleared Augmented Reality-Based Surgical Platform for Total Knee Replacement

EQS Group-Ad-hoc: Medacta Group SA / Key word(s): Regulatory Approval 
Medacta to Introduce NextAR: First FDA-Cleared Augmented Reality-Based 
Surgical Platform for Total Knee Replacement 
 
13-Jul-2020 / 07:00 CET/CEST 
Release of an ad hoc announcement pursuant to Art. 53 KR 
The issuer is solely responsible for the content of this announcement. 
 
*Press Release* 
 
*Medacta to Introduce NextARTM: First FDA-Cleared Augmented Reality-Based 
Surgical Platform for Total Knee Replacement* 
 
*- *Milestone achievement in orthopaedic technology further strengthens 
Medacta's profile 
 
- New surgical platform has the potential to improve surgical efficiency 
with economic benefits to the healthcare system 
 
- Enhanced visualization via augmented reality boosts Medacta's personalized 
medicine offering 
 
_CASTEL SAN PIETRO, 13 July 2020_ - Medacta today announced it has received 
clearance from the U.S. Food and Drug Administration (FDA) for its NextARTM 
Augmented Reality based surgical platform for total knee arthroplasty (TKA) 
procedures. 
 
The NextARTM TKA is the first application of a new platform technology, 
which will be extended to hip, shoulder and spine procedures, designed and 
engineered with Artificial Intelligence and Machine Learning that make 
pre-operative CT-based planning and analysis efficient and precise. 
 
The NextARTM TKA Application has the goal to improve efficiency and 
precision in total knee replacement and deliver personalized planning, with 
low upfront capital investment required by clinics and hospitals, as well as 
economic benefits to the healthcare system through OR efficiency and low 
cost per procedure. This new platform will be an optimal solution 
particularly for U.S. ambulatory surgery centers (ASCs), which provide 
same-day surgical care. 
 
The Augmented Reality glasses provided with the NextARTM Platform allow the 
surgeon to visualize surgical actions and information in real-time, directly 
on the operative field. This improves the user experience and helps the 
surgeon remain focused on the patient at all times. 
 
"With enhanced visualization via augmented reality, the NextARTM Platform is 
an innovative and efficient tool for ultra-precise, patient-specific 
treatment," said Dr Michael McAuliffe (MBBS FRACS), an orthopaedic surgeon 
at St Andrew's Ipswich Hospital in Queensland, Australia, and a member of 
the expert surgeon panel that Medacta collaborated with to develop the 
NextARTM TKA Application. "With the NextARTM TKA Application, we are able to 
track 3D soft tissue behavior during a surgery in real time. This 
functionality is an exciting advancement from traditional computer-assisted 
or robotic-assisted surgical systems that only track the relative movement 
of the knee bones, not the actual soft tissue." 
 
The NextARTM TKA Application, with a precise reconstruction of the patient 
bone morphology, allows direct tracking of the collateral ligaments and a 3D 
analysis of soft tissue behavior throughout the whole range of motion during 
surgery, bringing patient-specific ligament balancing to the next level. 
 
In addition to advanced planning tools, Medacta has developed the NextARTM 
TS, a revolutionary infrared single-use tracking system that has the 
potential to vastly improve surgery efficiency while helping surgeons 
execute pre-op plans. 
 
"The new NextARTM TKA Application allows for great precision and control, 
ultimately translating to great efficiency in the operating room," said 
Jonathan Vigdorchik, M.D., an orthopaedic surgeon at the Hospital for 
Special Surgery (HSS) in New York and collaborator on this platform. 
"Particularly in today's environment, as surgeons and health systems look to 
recover surgeries that were deferred during the COVID-19 pandemic, 
efficiency in the operating room will become even more crucial than before. 
The NextARTM Platform with its Single-Use Infrared Tracking System will be a 
valuable solution to meet these new levels of market demand." 
 
The NextARTM TKA works in conjunction with the Medacta GMK Sphere Medially 
Stabilized Knee implant, which has been proven to facilitate restoration of 
natural patient-specific kinematics. 
 
"We are proud to be part of the NextARTM Platform project that represents 
the next step forward for personalized medicine in orthopaedics," said PD 
Dr. med. Sandro Fucentese, Head of Knee Surgery at the Balgrist University 
Hospital and collaborator on this platform. "For many years we have been 
collaborating with Medacta in developing personalized solutions that have 
been relevant at the global level. The NextARTM Platform perfectly fits into 
this philosophy relying on a solid and established ecosystem and expertise." 
 
Francesco Siccardi, CEO of Medacta, said: "Patients and surgeons are 
attracted by improved outcomes and innovation, the NextARTM Platform is one 
Medacta answer to the current race in orthopaedic technology and I am very 
excited about this milestone achievement. Requiring a very limited 
investment in capital equipment, the NextARTM Platform perfectly represents 
Medacta's commitment to develop solutions that are able to improve patient 
outcomes and healthcare system sustainability." 
 
For more information on the NextARTM Platform, please visit 
nextar.medacta.com [1] 
 
*Contact* 
Medacta Group SA 
Corrado Farsetta, CFO 
Phone: +41 91 696 60 60 
investor.relations@medacta.ch 
 
*About Medacta* 
Medacta is an international company specialized in the design and production 
of innovative orthopaedic products and the development of accompanying 
surgical techniques for joint replacement, spine surgery, and sports 
medicine. Established in 1999 in Switzerland, Medacta's products and 
surgical techniques are characterized by innovation. Medacta is a pioneer in 
developing new offerings on the basis of minimally invasive surgical 
techniques, in particular its Anterior Minimally Invasive Surgery (AMIS) 
technique for hip replacements. Medacta has leveraged its orthopaedic 
expertise and comprehensive understanding of the human body to develop the 
sophisticated MySolutions technology, which offers surgeons highly 
personalized pre-operative planning and implant placement methodologies by 
creating advanced personalized kinematic models and 3D planning tools for 
use in hip, knee, shoulder and spine procedures. 
 
End of ad hoc announcement 
Language:    English 
Company:     Medacta Group SA 
             Strada Regina 
             6874 Castel San Pietro 
             Switzerland 
Phone:       +41 91 696 6060 
E-mail:      info@medacta.ch, investor.relations@medacta.ch 
Internet:    www.medacta.com 
ISIN:        CH0468525222 
Listed:      SIX Swiss Exchange 
EQS News ID: 1091815 
 
End of Announcement EQS Group News Service 
 
1091815 13-Jul-2020 CET/CEST 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=f7f89e14d55c089dd6bd1661bff6069b&application_id=1091815&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

July 13, 2020 01:01 ET (05:01 GMT)

TOTAL-Aktie komplett kostenlos handeln - auf Smartbroker.de
© 2020 Dow Jones News
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.